| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA419: Apremilast for treating moderate to severe plaque psoriasis (replaced TA368) |
|
Medicine details |
|
| Medicine name | apremilast (Otezla®) |
| Formulation | 10 mg, 20 mg, 30 mg film-coated tablet |
| Reference number | 1711 |
| Indication | Oztela is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) |
| Company | Celgene |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/01/2015 |
| NICE guidance | TA419: Apremilast for treating moderate to severe plaque psoriasis (replaced TA368) |